Contents

Introduction 1

1. General policy 3

1.1 Cross-cutting pharmaceutical quality assurance issues 3

1.2 International collaboration 6

2. Quality control - specifications and tests 8

2.1 *The International Pharmacopoeia* 8

2.1.1 Updates 8

2.1.2 Workplan 2016-2017 8

2.2 Specifications for medicines, including children's medicines and radiopharmaceuticals 10

2.2.1 Maternal, newborn, child and adolescent health medicines 10

2.2.2 Antituberculosis medicines 11

2.2.3 Antiviral medicines 12

2.2.4 Medicines for tropical diseases 12

2.2.5 Other anti-infective medicines 13

2.2.6 Other medicines 14

2.2.7 Radiopharmaceuticals 14

2.3 General monographs for dosage forms and associated method texts 15

2.4 General policy 16

3. Quality control - International Reference Materials (International Chemical Reference Substances and Infrared Reference Spectra) 20

4. Quality control - national laboratories 21

4.1 External Quality Assurance Assessment Scheme (EQAAS) 21

4.2 Guidance on testing of "suspect" substandard/spurious/falsely-labelled/falsified/ counterfeit medicines 21

4.3 Recommendations from the meeting on regulatory guidance for multisource products 22

5. Prequalification of quality control laboratories 23

5.1 Update on the prequalification of quality control laboratories 23

5.2 Update on WHO quality monitoring projects 23

5.3 Revision of the procedure for assessment of quality control laboratories 24

6. Quality assurance - collaboration initiatives 25

6.1 International meetings of world pharmacopoeias 25

6.2 Good pharmacopoeial practices 25

6.3 Inspection guidelines and good practices 26

7. Quality assurance - good manufacturing practices 27

7.1 Update of WHO good manufacturing practices: validation 27

7.2 Heating, ventilation and air-conditioning (HVAC) 27

7.3 Update and recommendations from the inspectors'meeting 28

8. Regulatory frameworks 29

8.1 Local manufacturing of essential medicines 29

8.2 WHO Global Model Regulatory Framework for Medical Devices 30

9. Regulatory guidance 31

9.1 Biowaiver list based on the WHO List of Essential Medicines 31
9.2 International Comparator Products List for equivalence assessment of interchangeable multisource (generic) products 31
9.3 Good regulatory practices 32
9.4 Collaborative procedure for stringent regulatory authority-approved medicines 32
9.5 Recommendations from the meeting on regulatory guidance for multisource products 33

10. Prequalification of priority essential medicines and active pharmaceutical ingredients 37

10.1 Update on the prequalification of medicines 37
10.2 Update on the prequalification of APIs 37

11. Nomenclature, terminology and databases 39

11.1 Quality assurance terminology 39
11.2 International Nonproprietary Names (INN) for pharmaceutical substances 39
11.3 Revision of guidance on representation of graphic formulae 39

12. Closing remarks 41

13. Summary and recommendations 42

Acknowledgements 48

Annex 1

WHO guidelines for selecting marker substances of herbal origin for quality control of herbal medicines 71

Annex 2

The International Pharmacopoeia: revised concepts and future perspectives 87

Annex 3

Prequalification of quality control laboratories: procedure for assessing the acceptability, in principle, of quality control laboratories for use by United Nations agencies 91

Annex 4

WHO Global Model Regulatory Framework for Medical Devices including in vitro diagnostic medical devices 103

Annex 5

General background notes on the list of international comparator pharmaceutical products 179

Annex 6

Equilibrium solubility experiments for the purpose of classification of active pharmaceutical ingredients according to the Biopharmaceutics Classification System, as an appendix to the WHO guidelines on *Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability* (Annex 7, WHO Technical Report Series, No. 992,2015) 181